You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方(09926.HK)急涨10%重越10天线 获大和首予「买入」评级看45元
阿思达克 11-03 13:51
康方生物-B(09926.HK)获大和首予「买入」评级看45元,该股继昨天再度考验上市低位22.1元不破,今天股价急弹重越10天线(24.8元),最高见26.6元,现造25.4元,急弹10%,成交倍增至388万股,涉资9,730万元。

康方先後公布,公司核心自主研发新药PD-1/VEGF双特异性抗体(研发代号:AK112)已在澳洲和中国开展Ia期临床研究,最初剂量递增阶段的临床研究结果令人鼓舞。此外,公司核心自主研发兼全球首创新型肿瘤免疫治疗新药Cadonilimab(PD-1/CTLA-4双特异性抗体,研发代号:AK104)用於经标准治疗後复发或转移性宫颈鳞癌的阶段性数据已在2020中国肿瘤免疫治疗会议上发布。

大和资本首次给予康方生物「买入」评级看45元,认为市场可能低估该制药公司阵营潜力。因为康方旗下有9种药物正在临床试验中,有3种药物即将进入临床试验,加在一起最高收入将达350亿人民币。随着新药penpulimab推出,康方2021年将实现其首笔产品销售收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account